Cure for small cell lung cancer

Before clarifying the treatment method of small cell lung cancer, we should first understand the characteristics of small cell lung cancer. Small cell lung cancer accounts for about 20% of lung cancer and has the characteristics of high malignancy, rapid tumor growth, and early metastasis. It is sensitive to chemotherapy and radiotherapy, and has a high initial remission rate, but it is very easy to develop secondary drug resistance and relapse.

Small cell lung cancer is indeed not suitable for surgical treatment. It is difficult to remove. If it is removed, the affected area is large and the patient is seriously injured. The early metastasis of small cell lung cancer also determines that surgery is not very meaningful. In addition, small cells are very prone to secondary drug resistance, and cancer cells are prone to recurrence. After cancer cells metastasize, systemic treatment should be the main treatment, which brings great difficulties to treatment. Therefore, tumor multi-cell immunotherapy combined with radiotherapy and chemotherapy, or tumor multi-cell immunotherapy alone is a better choice.

It is generally believed that small cell lung cancer originates from argyrophilic cells in the bronchial mucosa or glandular epithelium and is an APUD tumor. Some people also believe that it originates from stem cells in the bronchial mucosal epithelium that can differentiate into neuroendocrine. Small cell lung cancer is the least differentiated and most malignant type of lung cancer. Most small cell lung cancers are central, close to the hilum of the lung. When 70% to 90% of patients are diagnosed, they are already in the middle and late stages and have lymph node or distant metastasis (brain metastasis, bone metastasis or liver metastasis). Therefore, after the patient is diagnosed, he must be hospitalized immediately for treatment. A delay of one day will lead to the risk of further deterioration.

Tumor multi-cell immunotherapy is developed on the basis of cytology and immunology, advocating the concept of "systemic treatment of local tumors". Tumor multi-cell immunotherapy is a cancer treatment technology developed on this basis, which has a great killing power on residual cancer cells and dormant cancer cells in the body, reducing the chance of cancer cell recurrence and metastasis.

Clinical data show that multi-cell tumor immunotherapy can enhance the sensitivity of chemotherapeutic drugs, reduce the toxic side effects of chemotherapeutic drugs, alleviate the pain of patients, improve the treatment effect, and has a very strong targeted effect on the treatment of small cell lung cancer.

For the treatment of small cell lung cancer, tumor multi-cell immunotherapy is chosen. By adding tumor antigens and specific factors to the patient's own cells in the laboratory, they are cultivated into more active and larger immune cells. After being transfused back into the patient's body, the patient's own immune system becomes stronger, thereby killing cancer cells and achieving the purpose of treating small cell lung cancer.